GALNT11

Across TCGA pan-cancer cohorts, GALNT11 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GALNT11 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher GALNT11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GALNT11 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, HNSC, and UCEC are the cancer types where GALNT11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	III,IV	0.037	0.750	<.001	36	view →
HNSC	DFS	Median	All	0.122	0.710	.001	33	view →
UCEC	DFS	Median	All	1.000	0.617	.003	18	view →
CESC	OS	Median	II,III,IV	0.203	0.759	.021	12	view →
LUAD	DFS	Median	All	0.319	0.678	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GALNT11–KIRC (DFS)

Open the KIRC breakdown →